NGS products
Next generation sequencing (NGS) can detect and analyze the gene status of tumor driver genes, tumor suppressor genes, prognosis-related genes, and genetic susceptibility genes at the molecular level through high-throughput sequencing, thereby helping pat
Products
HRD/HRR testing
Synthetic lethality is another important direction of anti-tumor drug discovery since molecular targeted therapy. Tumor cells can recognize damaged DNA and activate their own repair mechanisms to repair it, thus becoming resistant to anti-cancer drugs. Therefore, blocking the repair pathway of DNA with specific drugs can increase the cytotoxicity of antitumor drugs, reverse drug tolerance, and improve the therapeutic effect. This is the phenomenon of synthetic lethality caused by drug blockade of the repair pathway in tumor cells with pre-existing HRD.
PARP inhibitors provide an effective and immediately available therapeutic alternative to chemotherapy for patients with HRD by interfering with the cell's ability to repair single-stranded DNA, which in combination with HRD causes synthetic lethality.
OncoCruise DNA Damage Repair 92 Genetic Testing
Product Description
HRR genetic testing products (germline + system) can meet a variety of clinical needs by detecting 92 genes related to DNA damage repair in one test, resolving DNA repair genes, drug-related genes and tumor susceptibility genes, and providing gene mutations for relevant drug matching and genetic risk assessment.
Clinical Significance
1、Include HER2 amplification assay to guide the use of HER2-targeted drugs such as trastuzumab and pertuzumab.
2、The test panel covers all coding regions of BRCA1/2 gene, providing dosing guidance for the application of PARP inhibitors olaparib and rucaparib in breast and ovarian cancers.
3, including PIK3CA gene test, providing dosing guidance for breast cancer targeted drug Alpelisib.
4、The test panel covers DDR-related genes, providing enrollment reference information for PARP inhibitor clinical trials in pancreatic cancer, prostate cancer, breast cancer, cervical cancer and endometrial cancer.
5、Matching samples to detect germline mutations in genetic risk-related genes for breast, ovarian, cervical, endometrial, prostate, pancreatic and colorectal cancers, aiding genetic oncogene detection.
Beneficial population
1、Tumor patients with PARP inhibitor drug needs
2、People with genetic screening needs
Sampling Guidelines
Tissue sample
Blood sample
